Nurix Therapeutics, Inc. Ratios

Ratios Nov2019 Nov2020 Nov2021 Nov2022 Nov2023 Nov2024
Profitability
EBT Margin -68.97%-357.90%-393.49%-466.93%-186.98%-354.36%
EBIT Margin -71.46%-364.66%-396.26%-476.01%-201.41%-390.52%
EBITDA Margin -71.46%-364.66%-396.26%-476.01%-201.41%-390.52%
Operating Margin -71.46%-364.66%-396.26%-476.01%-201.41%-390.52%
Net Margin -69.74%-242.42%-393.93%-466.93%-186.98%-354.85%
FCF Margin -3.37%-26.00%-302.61%-445.42%-116.60%-333.38%
Efficiency
Assets Average 220.20M436.56M446.76M386.18M512.47M
Equity Average 116.28M316.29M323.00M252.09M363.74M
Invested Capital -57.71M290.27M342.30M303.70M200.49M526.99M
Asset Utilization Ratio 0.080.070.090.200.11
Leverage & Solvency
Equity Ratio -1.310.730.720.730.560.79
Valuation
Enterprise Value -37.72M1,374.87M990.02M221.74M13.79M956.61M
Market Capitalization 1,656.02M1,285.74M530.88M301.69M1,566.19M
Return Ratios
Return on Sales -0.70%-2.42%-3.94%-4.67%-1.87%-3.55%
Return on Capital Employed -0.37%-0.32%-0.49%-0.52%-0.51%
Return on Invested Capital -0.38%
Return on Assets -0.20%-0.27%-0.40%-0.37%-0.38%
Return on Equity -0.37%-0.37%-0.56%-0.57%-0.53%